[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100216814":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":10,"locations":10,"responsibleParty":26,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":10,"eligibilityCriteria":34,"healthyVolunteers":35,"sex":36,"minAge":10,"maxAge":10,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lansoprazole 15 mg",null,"Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.",[13],"Drug: Lansoprazole",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Lansoprazole","Lansoprazole Capsules 15 mg\u002F Orally Disintegrating (OD) Tablets 15 mg",[9],[21],"Takepron Capsules 15 mg, Takepron Orally Disintegrating (OD) Tablets 15 mg",[23],{"name":24,"affiliation":5,"role":25},"Postmarketing Group Manager","STUDY_CHAIR",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100216814","long-term-use-of-takepron-on-the-prevention-of-recurrence-of-gastricduodenal-ulcer-in-patients-receiving-non-steroidal-anti-inflammatory-drugs-100216814",true,"NCT02099708","Long-term Use of Takepron on the Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs","Takepron Capsules 15\u002F Orally Dispersing（OD） Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs","Inclusion Criteria:\n\n* (1) Patients with a history of gastric or duodenal ulcers (2) Patients requiring long-term use of NSAIDs for reasons such as pain management for rheumatoid arthritis or osteoarthritis (3) Patients taking oral NSAIDs at the start of administration of lansoprazole (including patients who start NSAIDs on the same day as the start of administration of lansoprazole)\n\nExclusion Criteria:\n\n* (1) Patients with gastric or duodenal ulcer (in the active \\[A1, A2\\] or healing \\[H1, H2\\] stage if assessed endoscopically) at the start of administration of lansoprazole (2) Patients with active upper gastrointestinal hemorrhage at the start of administration of lansoprazole (3) Patients with contraindications for lansoprazole",false,"ALL",{"count":38,"type":39},3502,"ACTUAL","OBSERVATIONAL","The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) therapy for up to 12 months in the routine clinical setting in patients receiving oral non-steroidal anti-inflammatory drugs (NSAIDs)",[43],"Gastric or Duodenal Ulcers",[45],"Pharmacological therapy","COMPLETED","2016-09-23",{"date":49,"type":50},"2016-10-27","ESTIMATED",{"date":52,"type":10},"2010-10",{"date":54,"type":39},"2014-03",{"name":5,"class":6}]